Suppr超能文献

脂蛋白相关磷脂酶A2和C反应蛋白用于短暂性脑缺血发作患者的风险分层

Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA.

作者信息

Cucchiara Brett L, Messe Steve R, Sansing Lauren, MacKenzie Larami, Taylor Robert A, Pacelli James, Shah Qaisar, Kasner Scott E

机构信息

Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA.

出版信息

Stroke. 2009 Jul;40(7):2332-6. doi: 10.1161/STROKEAHA.109.553545. Epub 2009 May 21.

Abstract

BACKGROUND AND PURPOSE

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a marker of unstable atherosclerotic plaque, and is predictive of both primary and secondary stroke in population-based studies.

METHODS

We conducted a prospective study of patients with acute TIA who presented to the ED. Clinical risk scoring using the ABCD(2) score was determined and Lp-PLA(2) mass (LpPLA(2)-M) and activity (LpPLA(2)-A) and high-sensitivity C-reactive protein (CRP) were measured. The primary outcome measure was a composite end point consisting of stroke or death within 90 days or identification of a high-risk stroke mechanism requiring specific early intervention (defined as >or=50% stenosis in a vessel referable to symptoms or a cardioembolic source warranting anticoagulation).

RESULTS

The composite outcome end point occurred in 41/167 (25%) patients. LpPLA(2)-M levels were higher in end point-positive compared to -negative patients (mean, 192+/-48 ng/mL versus 175+/-44 ng/mL, P=0.04). LpPLA(2)-A levels showed similar results (geometric mean, 132 nmol/min/mL, 95% CI 119 to 146 versus 114 nmol/min/mL, 95% CI 108 to 121, P=0.01). There was no relationship between CRP and outcome (P=0.82). Subgroup analysis showed that both LpPLA(2)-M (P=0.04) and LpPLA(2)-A (P=0.06) but not CRP (P=0.36) were elevated in patients with >50% stenosis. In multivariate analysis using cut-off points defined by the top quartile of each marker, predictors of outcome included LpPLA(2)-A (OR 3.75, 95% CI 1.58 to 8.86, P=0.003) and ABCD(2) score (OR 1.30 per point, 95% CI 0.97 to 1.75, P=0.08).

CONCLUSIONS

Many patients with TIA have a high-risk mechanism (large vessel stenosis or cardioembolism) or will experience stroke/death within 90 days. In contrast to CRP, both Lp-PLA(2) mass and activity were associated with this composite end point, and LpPLA(2)-A appears to provide additional prognostic information beyond the ABCD(2) clinical risk score alone.

摘要

背景与目的

脂蛋白相关磷脂酶A2(Lp-PLA2)是不稳定动脉粥样硬化斑块的标志物,在基于人群的研究中可预测原发性和继发性卒中。

方法

我们对就诊于急诊科的急性短暂性脑缺血发作(TIA)患者进行了一项前瞻性研究。采用ABCD2评分进行临床风险评分,并测定Lp-PLA2质量(LpPLA2-M)、活性(LpPLA2-A)和高敏C反应蛋白(CRP)。主要结局指标是一个复合终点,包括90天内发生卒中或死亡,或识别出需要特定早期干预的高危卒中机制(定义为与症状相关血管狭窄≥50%或有需要抗凝治疗的心脏栓塞源)。

结果

167例患者中有41例(25%)出现复合结局终点。与终点阴性患者相比,终点阳性患者的LpPLA2-M水平更高(均值分别为192±48 ng/mL和175±44 ng/mL,P=0.04)。LpPLA2-A水平也有类似结果(几何均值分别为132 nmol/min/mL,95%CI为119至146;以及114 nmol/min/mL,95%CI为108至121,P=0.01)。CRP与结局之间无相关性(P=0.82)。亚组分析显示,狭窄≥50%的患者中,LpPLA2-M(P=0.04)和LpPLA2-A(P=0.06)均升高,但CRP未升高(P=0.36)。在使用每个标志物上四分位数定义的切点进行的多变量分析中,结局的预测因素包括LpPLA2-A(比值比3.75,95%CI为1.58至8.86,P=0.003)和ABCD2评分(每增加1分比值比1.30,95%CI为0.97至1.75,P=0.08)。

结论

许多TIA患者存在高危机制(大血管狭窄或心脏栓塞)或在90天内会发生卒中/死亡。与CRP不同,Lp-PLA2的质量和活性均与这一复合终点相关,且LpPLA2-A似乎能提供超出ABCD2临床风险评分的额外预后信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验